Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies...
| Հիմնական հեղինակներ: | , , , , , , , , , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Frontiers Media S.A.
2021-05-01
|
| Շարք: | Frontiers in Pharmacology |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.frontiersin.org/articles/10.3389/fphar.2021.680021/full |